Abstract Perhaps one of the most important developments in head and neck oncology of the past decade is the demonstration that patients with human papillomavirus (HPV)-mediated oropharyngeal cancers have significantly improved outcomes, compared to HPV-negative counterpart patients. This has become the basis for clinical trials investigating the impact on ''treatment deintensification'' for patients with HPV-mediated oropharyngeal cancers. Unfortunately, the significance of HPV in non-oropharyngeal head and neck cancers is much less certain. Our goal is to systematically review the published data regarding the role HPV in carcinomas of the oral cavity, larynx, sinonasal tract and nasopharynx with respect to HPV detection frequency, viral activity, and association with outcome. We also present preliminary data on HPV16/18 transcriptional status in oral cavity carcinomas, as well as salivary gland neoplasia, as determined by nested reverse transcription PCR for HPV E6/E7 RNA. The weighted prevalence (WP) of HPV DNA detection in 4,195 oral cavity cancer patients is 20.2 %, (95 % CI 16.0 %, 25.2 %). HPV16 is the most common type detected. Importantly, no data currently demonstrates a significant association between the presence of HPV DNA and improved outcome. The WP of HPV DNA in 1,712 laryngeal cancer patients is 23.6 %, (95 % CI 18.7 %, 29.3 %). Similarly, no association has yet been demonstrated between HPV DNA status and outcome. The WP of HPV DNA detection in 120 sinonasal cancer patients is 29.6 % (95 % CI 17.8 %, 44.9 %), and in 154 nasopharyngeal carcinoma patients is 31.1 %, (95 % CI 20.3 %, 44.5 %). Recent preliminary data also suggests an association between HPV and certain salivary gland neoplasms. The clinical significance of these findings is unclear. The published data strongly support the need for studies on patients with oral and laryngeal carcinomas that will be powered to find any differences in clinical outcome with respect to HR-HPV and p16 overexpression.
Introduction
Perhaps one of the most important developments in head and neck oncology of the past decade is the demonstration that patients with human papillomavirus (HPV)-mediated oropharyngeal cancers have significantly improved clinical outcomes, compared to patients with HPV-negative oropharyngeal carcinomas. Clinical trials are underway to investigate the impact of ''treatment deintensification'' for patients with HPV-mediated oropharyngeal cancers. The possibility of offering patients with HPV-mediated cancers less aggressive adjuvant therapy is especially relevant given the potential for devastating radiation toxicities. Can treatment deintensification strategies also be applied to HPV-positive cancers at non-oropharyngeal sites? Does the presence of HPV in non-oropharyngeal carcinomas represent viral-mediated carcinogenesis, or merely ''bystander'' infection? Lastly, even if HPV promotes carcinogenesis in non-oropharyngeal head and neck cancers, does it impact clinical outcome? Compared to the state of knowledge regarding HPV and oropharyngeal cancers, the significance of HPV in non-oropharyngeal head and neck cancers is unfortunately uncertain. These questions are especially important as laryngeal and oral cavity cancers are more common than oropharyngeal cancers.
Most publications focus on HPV DNA detection frequencies in non-oropharyngeal head and neck cancers, and only a few studies have directly addressed the impact of HPV on clinical outcome. The goal of this article is to systematically review the published data regarding the role of HPV in carcinomas of the oral cavity, larynx, sinonasal tract, and nasopharynx with respect to detection frequency, viral activity, and association with outcome. We also present some emerging data on HPV in salivary neoplasia.
Methods
The Pubmed search engine was used to identify studies published in English published from January 2000 through March 2012 using the MeSH terms ''HPV'', ''Human Papillomavirus'', ''Head and Neck Cancer'', ''Oral Cavity'', ''Laryngeal'', ''Larynx'', ''Sinonasal'', ''Nasal'', ''Nasopharynx'', and ''Polymerase Chain Reaction'' (PCR). Oral cavity includes tongue (excluding tongue base), gum, floor of mouth, buccal mucosa, and hard palate. Data regarding the hypopharynx was not abstracted, for concern of possible anatomic overlap with oropharynx. The following arbitrary restraints were placed on this review; we excluded nonEnglish manuscripts, manuscripts published before 2000, case reports, and investigations using non-PCR techniques or only in-situ PCR. If data were available using multiple techniques, only the PCR-generated data were extracted [1] . Only data generated from primary squamous cell carcinomas (SCC) were extracted, and we excluded reports if: (1) the detection methods were not well-detailed, and/or (2) HPV data could not be extracted per anatomic site. We took care to avoid tallying overlapping patient cohorts [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] . The final extracted data included: county, year of publication, anatomical site, HPV type, detection method of including primers, and summary of findings for cancers, patient controls, benign lesions, potentially premalignant lesions, and premalignant lesions, when available. For consistency, lowrisk HPV data were grouped together with ''HPV-positive, all types''. The weighted prevalence (WP) with 95 % confidence intervals (CI) was calculated using Comprehensive Meta-Analysis, version 2 (Meta-Analysis.com). Weights are based on the inverse variance from the random effects analysis which includes the ''within-studies'' variance plus the ''between-studies'' variance.
Results
One hundred publications fulfilled the above criteria and serve as the basis of this review; the great majority of them relied on HPV DNA detection by PCR analysis. Detection of HPV DNA supports the idea that HPV is ''associated'' with a cancer. However, it does not distinguish whether HPV is transcriptionally active and thus might promote carcinogenesis (e.g., ''driver'' infection) or transcriptionally inactive (referred to as ''passenger'' or ''bystander'' infection). The usual accepted criteria to support HPV-mediated carcinogenesis are: (1) demonstration of high-risk HPV E6/E7 RNA; (2) p16 overexpression; (3) viral integration; and lastly (4) wild type 53 protein. These criteria have important caveats. The p16 gene may be methylated in HPV-mediated cancers. HPV integration is not necessary for promoting carcinogenesis. Lastly, while the HR-HPV?/wild-type p53 profile is the expected genetic phenotype of neversmokers with HPV-mediated oropharyngeal cancers, this polarized relationship is not observed in patients with oral cavity cancer, as will be discussed [101] . Furthermore, nondisruptive p53 mutations can be demonstrated in HPV-mediated head and neck cancers, and are thought to have an additive impact on overall p53 functional loss [102] .
HPV and Cancers of the Oral Cavity [34, 37, 79] . The difference in the WP between oral verrucous carcinomas and usual-type SCC is not statistically significant (p = 0.15); this is probably due to the small number of oral verrucous carcinomas studied, and the wide 95 % confidence intervals.
The most common HPV type detected in oral cancers is HPV16. A notable outlier is a study from South Africa which detected only HPV18, and not HPV16, in patients with oral cancer [23] . HPV18 was detected in a smaller percentage of oral cancers, some oral carcinomas had dual infections with HPV16/18 [51, 70, 96] . Rarer types detected in oral cancers were HPV8, HPV31, HPV38, and HPV66 [56, 68, 93] . Low-risk HPV is rarely detected in oral cancers, and when present might represent a ''bystander'' infection rather than possibly ''driver'' infection [37, 42, 64, 68, 80] . HPV RNA and Oral Cavity Cancer
As mentioned, demonstrating viral oncogene transcription suggests, but does not prove, that viral-mediated carcinogenesis is mechanistically possible (''driver infection'').
There is a paucity of published data regarding HR-HPV E6/E7 RNA in oral cancers [3, 7, 21, 81, 85] . The common approach of these studies is to perform reverse-transcription PCR on HPV-positive cancers. Only four studies demonstrated that HR-HPV E6/E7 RNA were present in a total of 17/20 (85 %) HPV-positive oral carcinomas tested [3, 7, 21, 85] . Another approach is to perform parallel PCR and reverse-transcription PCR assays for all specimens [81] . In a study of 109 patients with head and neck cancer from multiple anatomic sites, three oral cancers were DNA?/ RNA-(reflecting either low-level or no transcription, and possibly ''passenger'' infections), three oral cancers were DNA?/RNA? (possibly driver infections), and four other cancers were DNA-/RNA? [81] . This last set of HPV transcriptionally-active, yet DNA-negative carcinomas is still consistent with the possibility of HPV-mediated carcinogenesis, and speaks to the idea of greater detection sensitivity of reverse-transcription PCR compared with PCR. We have studied a cohort of 89 consecutive patients with oral cavity SCC, and determined the rate of HPV16/18 E6/E7 RNA, by nested reverse transcription PCR on archival tumor samples (unpublished data). We demonstrated that 30 patients (33.7 %) had either HPV16 or HPV18; no double infections were present.
HPV, Oral Cavity Carcinoma, and Outcome Only three published studies on patients with oral cavity carcinoma specifically examined the impact of HPV on outcome [51, 89, 101] . Kaminagakura studied 114 patients and found a nonsignficant trend towards improved survival for 22 HPV-positive patients [51] . Sugiyama studied 66 patients in total, 62 with outcome data; 23 of these patients were HPV-positive [89] . They demonstrated a nonsignficant trend towards improved overall survival for HPVpositive oral cavity cancer patients [89] . Smith found no association with HPV and outcome for patients with oral carcinoma, based on either serology (116 patients, 13 with HPV positive serology) or tumor HPV detection (100 patients, 12 with tumors positive for HR-HPV DNA) [101] . Interestingly, in our unpublished cohort of 89 patients with oral cavity carcinoma, no significant association was found for patients with either HPV16/18 E6E7 RNA and time to disease progression or disease specific survival.
Oral HPV in Control Populations [103] . Some of the relatively larger studies from India [30] , Scandinavia [60] , and China [96] demonstrate significantly greater oral HPV carrier rates as compared to the other studies, suggesting that real geographic differences may be present. The WP of intraoral HPV detection is significantly lower than the rate of HPV detection in oral carcinomas (6.9 vs. 20.2 %, respectively, p = 0.0002). The findings suggest that HPV may contribute to oral cancer carcinogenesis. However, this relationship does not establish causality.
HPV in Benign, Potentially Premalignant, and Premalignant Oral Lesions Table 3 addresses the issue of HPV detection frequency in a spectrum of oral lesions, summarizing cross-sectional data for DNA detection (all HPV types) in patients with Ten reports studied a group of lesions classified as ''potentially premalignant'' oral lesions (leukoplakia, lichen planus, submucous fibrosis); HPV DNA was detected in 54/144 lesions; the WP is 41.4 %, (95 % CI 25.8 %, 58.9 %), which is also significantly higher than the intraoral HPV carrier rate. This also suggests that HPV may also promote potentially premalignant lesions, although it does not establish causality. Finally, only two studies investigated premalignant oral lesions (high-grade dysplasia): HPV was detected in 6/63 (9.5 %) of cases. No conclusions can be made due to the paucity of data.
Interestingly, one small study demonstrated that patients with submucous fibrosis demonstrated the highest HPV prevalence (11/12, or 91.7 %) [49] . Oral submucous fibrosis is a potentially premalignant condition caused by areca nut chewing and histologically characterized by increased submucosal collagen deposition and squamous mucosal atrophy. Access to basal reserve cells is required for establishing HPV mucosal infection. The transitional zone between uterine ectocervix and endocervix is an example of a region particularly vulnerable to HPV infection. It is possible that oral mucosal atrophy due to submucous fibrosis allows for greater exposure of epithelial basal cells, and therefore greater vulnerability to HPV infection. There is a need to follow-up with larger studies investigating the incidence of HPV in patients with betel nut-induced submucous fibrosis.
HPV and Cancers of the Larynx
Disproportionately fewer laryngeal cancers have been studied for HPV as compared to oral cancers (1,712 vs. 4,195 , respectively) within the same time period (2000-2012) despite the fact that global incidences for these two cancers are on the same order of magnitude [104] . Table 4 summarizes the 41 publications on 1,712 patients with laryngeal SCC. HPV DNA has been detected in 436/1,712 laryngeal cancers; the WP is 23.6 %, (95 % CI 18.7 %, 29.3 %). No geographical differences were seen. Only three laryngeal verrucous carcinomas were studied, HPV was detected in 2/3 tumors, one was low-risk (LR) and the other was high-risk (HR) [39] .
The most common HPV type detected in laryngeal cancers is HPV16. Compared to oral carcinomas, a greater diversity of other HPV types has been detected: HPV18, HPV26, HPV31, HPV33, HPV39, HPV36, HPV45, HPV51, HPV52, HPV58, HPV59, HPV66, and HPV69 [8, 9, 14, 20, 26, 29, 39, 65, 71, 90, 94] . Low-risk HPV are uncommonly detected, and might represent incidental ''bystander'' rather than possibly ''driver'' infection [29, 39, 65, 75, 90, 94] . Rarely, integrated low-risk HPV has been found; viral integration does suggest viral-mediated carcinogenesis [90, 94] . Head and Neck Pathol (2012) 6:S104-S120 S109 
HPV, Laryngeal Carcinoma, and Outcome
Only four published studies, Duray [29] , Morshed [8, 9] , Stephen [88] , and Vlachtsis [95] examined the impact of HPV on the outcome of a total of 319 patients; 134 were HPV positive.
No association of HPV status with outcome was found. Table 5 addresses the issue of latent laryngeal HPV infection in control populations (usually autopsies or laryngeal brushings), and summarizes DNA detection data for five studies, all HPV types, in normal larynges. HPV DNA has been detected in 12/107 normal larynges; the WP is 9.6 %, (95 % CI 2.9 %, 27.2 %). There is a nonsignficant trend comparing the WP for laryngeal ''HPV carrier rate'' and HPV detection rate in laryngeal carcinomas, p = 0.11. This suggests that HPV might promote laryngeal cancer, but does not establish causality.
Laryngeal HPV in Control Populations

HPV in Other Laryngeal Lesions
The association of HPV6/11 with laryngeal papillomas is well-established [105] . On the other hand, very few studies have examined the rate of HPV detection in other benign laryngeal lesions. Morshed [8] did not find any HPV in 22 vocal cord nodules. Duray [29] studied 35 biopsies of vocal nodules (n = 20), chronic laryngitis (n = 13) and papillomas (n = 6) and detected HPV in 27/35 (77 %) of these specimens; however, the HPV detection rate was not subclassified by histology. Smith [10] [106] . The published data specifically regarding sinonasal SCC and HPV are quite sparse and suffers from heterogeneity with respect to association with IP. Table 6 summarizes 9 publications of 120 patients with sinonasal carcinoma: HPV DNA (all types) was detected in 31/120 cancers and the WP is 29.6 % (95 % CI 17.8 %, 44.9 %). HPV16 is most commonly detected. Because of the heterogeneity of this group, no conclusions can be drawn from this WP.
HPV RNA and Sinonasal SCC Only one publication looked at HPV transcriptional activity; two HPV? SCC arising ex-inverted papillomas also reveal HPV RNA transcription, and evidence of viral integration [66] . [97] . There are limited data regarding sinonasal HPV ''carrier'' rates. Hoffmann [46] found HPV in 1 of 39 (2.6 %) sinonasal polyps.
HPV in Nasopharyngeal Carcinoma (NPC)
There has been recent interest in the role of HPV in NPC. Table 7 summarizes the 8 PCR-based studies that include 154 patients with NPC. Six of these studies have been published within the last 3 years. HPV 16 was detected. An important caveat to consider is that carcinomas may be of oropharyngeal origin with extension into the contiguous nasopharynx, rather than represent primary NPC. Having said this, three recent studies examined the issue of HPV/ Epstein Barr virus (EBV) co-infection by various techniques [98, 99, 107] . These studies suggest a dichotomy of HPV?/EBV-NPC (14/68 cases, 20.5 %) versus HPV-/ EBV? NPC (40/80, 50 %) with no tumors harbouring double HPV/EBV infections [98, 99, 107] . However, NPC with double HPV/EBV infections have been reported [108] .
HPV RNA in NPC HPV RNA has been detected in the single HPV? NPC studied [81] .
HPV, NPC, and Outcome
Only one publication specified the outcomes for five patients with NPC, four of whom were HPV?/EBV-, and the remaining patient was HPV-/EBV? [98] . The limited nature of this data precludes further discussion.
HPV DNA in Salivary Neoplasia
The SEER 9 data demonstrates a trend of increasing incidence for mucoepidermoid carcinoma (MEC) in women, ages 15-34 years [109] reminiscent of the significantly increased incidence of oropharyngeal cancers over the past three decades due to HR-HPV-mediated carcinogenesis. This raises the interesting question as to whether HR-HPV can also be involved in MEC carcinogenesis [109] . The possibility of HPV promoting salivary tumors has been addressed in the literature in a limited manner. Vageli demonstrated HPV16/18 DNA in seven of nine parotid tumors, including an oncocytoma, acinic cell carcinoma, Warthin's tumor, and a pleomorphic adenoma [110] . While DNA detection does not address the issue of transcriptional activity, and therefore biological relevance, these authors demonstrated relatively high copy number by quantitative real-time PCR for some tumors, which suggests a causative relationship. Recently, Boland and colleagues demonstrated HR-HPV DNA in two of 16 salivary adenoid cystic carcinomas using the Ventana in situ hybridization (ISH) probes [111] . HPV DNA ISH is not the optimum technique 
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for initial exploratory studies. The detection sensitivity of ISH might be very good depending on the context. However, greater tumor sampling is accomplished by PCR on formalin-fixed, paraffin-embedded (FFPE) samples, as compared to ISH, and is therefore the preferred approach for initial exploratory studies.
HPV RNA in Salivary Neoplasia
We studied a cohort of 89 patients with MEC for high risk HPV E6/E7 RNA by nested reverse transcription PCR (unpublished data). A total of 42 patients (47.2 %) had either HPV 16 or 18, and seven (7.1 %) had both 16 and 18. Interestingly, there was no predilection of HPV positivity in minor salivary MEC as compared to MEC of the major glands. Eighty four cases were studied by IF with the monoclonal C1P5 antibody which detects E6 protein of both HPV16/18. Eighteen tumors displayed nuclear and or cytoplasmic tumor staining, and the protein was detected in both mucinous and squamoid elements (Fig. 1 ). All cases positive by IF were HPV16/18 positive by RT-PCR. Fourteen additional MEC were negative by IF and positive by RT-PCR. This preliminary data demonstrates that transcriptionally active HPV16/18 is common in MEC. Thus, HPV may possibly promote the carcinogenesis of these tumors. The significance of the HPV DNA and RNA in salivary neoplasia is presently unknown.
Discussion
Technical Considerations
Despite limiting this systematic literature review to PCRbased studies, the heterogeneity of published data begs the issue of technical considerations, and should be briefly addressed. The gold standard for HPV assay sensitivity is the detection of HPV RNA in frozen tissues [81, 85] . HPV RNA can be present in excess in HPV DNA, and snap frozen tissue does not undergo the extensive nucleic acid/ protein cross-linking and continuous DNA/RNA degradation found in FFPE samples. Most, but not all cited studies used FFPE samples. Tables 1 and 4 demonstrate that nested PCR using the MY09/MY11 consensus primers, and nested GP5?/GP6? consensus primers, is a very common approach. These consensus primers detect a broad spectrum of low-risk and high-risk mucosal HPV types [112] . However, there are two major limitations with this approach: (1) size of the region to be amplified; and (2) potential loss of the L1 gene.
The MY09/MY11 primers amplify a region 450 base pairs long, which is too long for amplifying FFPE samples. The GP5?/GP6? consensus primers detect a much smaller region, on the order of 150 bp. In general, a nested approach increases amplicon concentration, allowing for better amplicon visualization. However, nested PCR does not abrogate the initial sensitivity bottleneck of using the MY09/MY11 consensus primers. We recommend a nested approach using the GP5 ?/GP6 ? consensus primers for both rounds of PCR. The SPF10 (Short PCR Fragment) primers amplifies a region in the L1 gene only 65 bp long, so may be even more sensitive than the GP5?/GP6? primers; however, we have not had direct experience with these primers.
The second limitation is that these primers detect sequences in the L1 region which can be lost upon HPV integration. If HPV is present in both integrated and episomal forms, one would expect positive results. However, if HPV is entirely integrated, PCR using these consensus primers may result in a false negative reaction. This was nicely demonstrated by Duray [29] who detected HPV in an additional 36 % of laryngeal SCC when assayed using type-specific E6/E7 primers. These laryngeal carcinomas harbored HPV that was entirely integrated and resulted in false negative PCR with GP5?/GP6? primers, but positive PCR with E6/E7 type-specific primers. One can then use the CPIIG/CPI primer pair, which amplifies a 188-bp fragment in the highly conserved E1 ORF region of various skin and mucosal HPV, for specimens negative by PCR with GP5?/GP6? primers.
General Conclusions
This systematic literature review highlights the present state of our knowledge with respect to three fundamental questions: (1) Is HPV associated with cancers of oral cavity, larynx, sinonasal tract, nasopharynx, and salivary glands? (2) Is there a causative relationship? (3) If HPV mediates carcinogenesis in these sites, does this impart an improved survival akin to HPV-mediated oropharyngeal SCC? As mentioned, this is important as an improved survival could be exploited to develop new treatment strategies. Each non-oropharyngeal site will be summarized with respect to these questions.
HPV and Oral Cavity Cancer
Our systematic review, plus other published reviews support the idea that HPV is significantly present in a subgroup of oral cavity SCC, as compared to control populations; thus, HPV may possibly contribute to oral carcinogenesis. We find that the WP for HPV DNA detection in 60 studies on 4, 195 [115] .
There is limited published data to support causation in this context. Only four studies demonstrated HR-HPV E6/ E7 RNA to be present in a total of 17/20 (85 %) HPV positive oral carcinomas tested [3, 7, 21, 85] . We also mentioned our unpublished findings of HPV16/18 E6/E7 RNA in 33.7 % of 89 oral cavity SCC studied by nested reverse transcription PCR. Future studies should address the issue of HPV RNA in oral cavity SCC.
P16 expression status should also be studied specifically in this context of oral cavity SCC, with the important caveat that lack of p16 overexpression does not exclude the possibility of HPV-potentiated carcinogenesis. Most publications correlating p16 expression with HPV status study mixed groups of cancers from different anatomic sites [61, 81, 93] . These studies are not powered to determine the sensitivity and specificity of p16 overexpression as a surrogate biomarker for HPV-mediated oral cavity carcinogenesis. Importantly, future studies should utilize whole tissue section staining rather than tissue microarrays, and specifically document the intensity and distribution of p16 overexpression in oral cavity SCC to access test performance at various ''cut-points''.
With respect to etiology, the interaction between HPV, cigarettes, and alcohol exposure is more complex in the oral cavity as compared to the oropharynx. Smith recently reported that among heavy tobacco users, the risk of oropharyngeal carcinoma is greater in HPV-seronegative patients (adjusted OR = 11.0) compared with HPV-seropositive patients (adjusted OR = 4.7); among heavy alcohol users the risk is also greater in HPV-seronegative patients (adjusted OR = 24.3) compared to HPV-seropositive patients (adjusted OR = 8.5) [101] . This is consistent with the concept of mutually exclusive pathways of HPVmediated carcinogenesis versus cigarette/alcohol-mediated carcinogenesis for oropharyngeal cancers. However, Smith found a different relationship between HPV, tobacco and alcohol for oral cavity cancers. The oral cavity cancer risk among heavy tobacco users was greater in HPV-seropositive patients (adjusted OR = 3.5) compared to HPV-seronegative patients (adjusted OR = 1.4); among heavy alcohol users the risk is also greater for HPV-seropositive patients (adjusted OR = 9.8) compared with HPV-seronegative patients (adjusted OR = 3.1) [101] . This interaction also suggests that profiling tumor suppressor gene mutational status in oral cancers will not result in the predicted dichotomy anticipated in oropharyngeal cancers (HPV?/wild type p53/wild type Rb vs. HPV-/mutated p53/mutated Rb).
Importantly, no data currently supports the idea that HPV is significantly associated with improved outcome for patients with oral cancer. The studies by Kaminagakura [51] and Sugiyama [89] do reveal nonsignficant trends, towards improved survival for patients with HPV-positive cancers. Therefore, future studies on oral cavity SCC should be powered to address the important clinical issue of HPV status (as determined by PCR).
HPV and Laryngeal Cancer
Fewer studies have addressed the association of HPV in laryngeal cancer [113, 116, 117] . Kreimer reviewed 35 PCR-based studies on 1,435 patients with laryngeal SCC and determined the cumulative pooled prevalence for HPV to be 24.0 %, (95 % CI 21.8, 26.3) [113] . We have found the WP of HPV is 23.9 %, (range 0-100 %, 95 % CI 17.1 %, 30.9 %) in laryngeal cancers. Hobbs determined the OR for laryngeal cancer is 2.0 (95 % CI 1.2, 3.4) as compared to controls. The most common HPV type detected in laryngeal cancers is HPV16; HPV18 is the second most common HPV type. However, compared to oral carcinomas, a greater diversity of other HPV types has been detected in laryngeal cancers. Low-risk HPV are uncommonly detected, but cannot be summarily dismissed as ''bystander'' infections as integrated low-risk HPV has been found in laryngeal cancers.
Very few studies have addressed the issue of causation regarding HPV and laryngeal cancer. HPV transcriptional activity was addressed in a total of nine cancers from three studies [2, 21, 81] . Duray demonstrated that the HPV16 viral load in laryngeal cancers (median 504 copies) was significantly higher than in benign lesions (median 37 copies). This supports the idea of active HPV ''driver'' infection, and suggested viral-mediated carcinogenesis. Future studies should address the issue of HPV RNA in laryngeal SCC.
P16 expression status should also be studied in the context of laryngeal cancer, with the same recommendations as above (whole tissue sections, documenting intensity and distribution). Baumann studied a subgroup of 10 laryngeal SCC including 5 HPV? SCC and demonstrated good correlation [20] . Likewise, Laco also demonstrated good correlation between p16 overexpression and HPV status in 24 laryngeal SCC, 14 of which were HPV? by chromogenic in situ hybridization (CISH) [118] .
Importantly, only four studies [8, 9, 29, 88, 95] examined the impact of HPV on the outcome of a total of 319 patients; 134 of which were HPVpositive. No association of HPV status with outcome was found. Therefore, future studies on laryngeal SCC should be powered to address the important clinical issue of HPV status (as determined by PCR) and association with clinical outcome.
HPV and Sinonasal Cancer
The relationship between HR-HPV promoting malignant progression of inverted papillomas is well established. Future studies should focus on sinonasal SCC specifically unrelated to IP. Good correlation between HPV? status, detected by either PCR or ISH, and diffuse p16 overexpression, has been reported in sinonasal SCC, albeit in small numbers [97, [119] [120] [121] . Strong diffuse p16 expression cannot be accepted as a surrogate HPV biomarker in any untested context, as this pattern of overexpression has also been detected in HPV-negative sinonasal undifferentiated carcinoma [122] . The improved outcome associated with HPV? sinonasal SCC reported by Alos and colleagues [97] necessitates validation by other groups.
HPV and Nasopharyngeal Cancer
While recent studies suggest a exclusionary dichotomy between HPV-mediated NPC and EBV-mediated NPC [98] [99] [100] 102 ] NPC with double EBV/HPV infections have been reported [108] . An important caveat to future studies is the necessity for stringent exclusion of ''NPC'' which may have arisen from the oropharynx. With respect to HPV as a driver infection for NPC, three studies have demonstrated good correlation between HPV? NPC and p16 expression, albeit on a small number of patients [98, 99, 107] .
Nowhere is the possibility of ''treatment de-escalation'' more important that in the situation of skull base radiation, where the treatment related toxicities of optic nerve damage and osteoradionecrosis are most fearsome. Adequately powered, stringent studies comparing outcomes for patients with HPV-mediated NPC, EBV-mediated NPC, doubleinfected NPC, and ''null'' viral NPC may be challenging due to the relative rarity of NPC in western populations. However, these studies could have tremendous clinical impact.
HPV and Salivary Tumors
The emerging data demonstrate that HPV is detected in some benign and malignant salivary tumors. We have also mentioned our preliminary data on HPV16/18 E6/E7 RNA in MEC. Correlation of any biomarker or grading schema, with outcome for patients with salivary malignancies is extremely challenging given the overall rarity of even ''common'' salivary malignancies and the need for even larger sample sizes on multivariate analysis to account for a greater number of possible anatomic tumor sites.
In conclusion, high-risk HPV DNA is present in a significant proportion of oral and laryngeal cancers. There is limited published data on HPV-positive oral and laryngeal carcinomas regarding RNA expression, physical state (episomal vs. integrated), and correlation with tumor suppressor gene mutational status. Therefore, a causative relationship between HPV and these nonpharyngeal cancers has not yet been firmly established. Importantly, only few studies have attempted to correlate HPV status with clinical outcome. This review justifies the need for additional, appropriately powered, well-designed studies to examine the relationship of HPV status and clinical outcome for patients with oral and laryngeal cancer. High risk HPV DNA is also present in a significant proportion of sinonasal, nasopharyngeal, and salivary gland cancers, but the clinical significance of these findings in these malignancies has yet to be clearly defined.
